MBRX logo

MOLECULIN BIOTECH INC

MBRXNASDAQ
πŸ† #4844 by market capEarnings Mar 16 Β· PostUS Equity
$7.74β–Ό $0.19 (βˆ’2.40%)
Market closed Β· at close
πŸ””
Track MBRX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.4%
7dβ–Ό 5.7%
14dβ–Ό 10.4%
30dβ–² 19.3%
ytdβ–Ό 88.3%
1yβ–Ό 96.4%
🏦Market Cap
$8M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$7.57 – $8.40
52-Week Range
$3.22 – $222.80
Volume (shares)
49,495
Avg Volume (shares)
β€”
Shares Outstanding
1.0M
Next Earnings
2027-03-16

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-0.7
P/S Ratio
0.0x
EPS (TTM)
$-15.07
Dividend Yield
0.00%
Dilution (1yr)
+2267.0%
MBRX logo

MOLECULIN BIOTECH INC

MBRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$25Mβ–Ό βˆ’5.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$23Mβ–Ό βˆ’4.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
160Kβ–² +2267.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$9Mβ–² +$5M YoY
StockOtter Β· stockotter.space

About MOLECULIN BIOTECH INC

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·4d ago

Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance

Patent protection spans North America, Europe & Asia-Pacific Rim Korean decision to grant extends reconstitution protection into another key Asia-Pacific market, reinforcing a multi-layered portfolio spanning more than 2

GlobeNewsWireΒ·6d ago

Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout

- Completed treatment of all 90 patients in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML)

GlobeNewsWireΒ·10d ago

Moleculin Secures Australian Patent for Annamycin Formulation Technology

Patent strengthens intellectual property protection for preparation of preliposomal Annamycin lyophilizate

GlobeNewsWireΒ·12d ago

Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies

Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin's antitumor activity, not a bystander

GlobeNewsWireΒ·18d ago

Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting

First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML

GlobeNewsWireΒ·23d ago

Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027

Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML)